CD4 and infection: Further experiences with CCR5-targeted stem cell therapies will probably encourage the treatment of selected populations of young HIV-positive patients with multi-resistant infection and exhaustion of CD4 cells, as well as HIV-infected pediatric patients with rapidly progressing disease.